Pursuing better treatments to help patients feel better, longer.

Advancing palazestrant for breast cancer

Palazestrant (OP-1250), our lead candidate, is a once-daily oral medicine with best-in-class potential for metastatic breast cancer.

Current clinical trials

OPERA-01 Phase 3 study is for people with advanced and/or metastatic ER+/HER2- breast cancer that has progressed after CDK4/6 inhibitors and endocrine therapy.

Bring your passion, join our team and make your mark.

Life at Olema

We are fostering a culture of collaboration, understanding, and inclusion that celebrates diverse backgrounds and expertise. Looking to make a difference in oncology? Explore our job opportunities.

Olema's latest news and recent events.

May 9, 2025 Olema Oncology to Participate in Upcoming Investor Conferences
May 2, 2025 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
April 25, 2025 Olema Oncology Announces New Preclinical Data for OP-3136 Demonstrating Anti-Tumor Activity in Multiple Solid Tumor Models at AACR 2025
April 2, 2025 Olema Oncology Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)